Tokyo Tape
Sign in
← Ono Pharmaceutical

Annual report

4528.TEDINET S100TMQ7
Period2023-04-01 → 2024-03-31
Filed2024-06-21
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥502.7bn2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥447.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥361.4bn2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥309.3bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥292.4bn2019-04-01 → 2020-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥159.9bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥142.0bn2022-04-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥163.7bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥143.5bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥105.0bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥100.9bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥79.7bn2019-04-01 → 2020-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥128.0bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥112.7bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥80.5bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥75.4bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥59.7bn2019-04-01 → 2020-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥128.0bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥112.9bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥913.7bnat 2024-03-31Cons.Assets IFRS
Total assets¥882.4bnat 2023-03-31Cons.Assets IFRS
Total assets¥739.2bnat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥745.4bnat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥673.4bnat 2020-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥115.1bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥134.6bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥798.6bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥747.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥661.7bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥793.0bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥741.9bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥655.9bnat 2022-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥634.1bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥562.5bnat 2020-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥166.1bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥96.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥69.1bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥61.0bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥69.0bnat 2020-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥110.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥159.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥61.8bn2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.0bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.2bn2019-04-01 → 2020-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow¥48.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥100.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥6.0bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥57.6bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥10.2bn2019-04-01 → 2020-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥89.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥32.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.2bn2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥24.8bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥54.7bn2019-04-01 → 2020-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥266.612023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥230.852022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥162.192021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥151.112020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥118.472019-04-01 → 2020-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥266.572023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥230.792022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥162.162021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥151.092020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥118.452019-04-01 → 2020-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥1,688.43at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,519.19at 2023-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,343.4at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,270.45at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥1,126.95at 2020-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio86.8%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio84.1%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio88.7%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio85.1%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio83.5%at 2020-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE16.7%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE16.1%2022-04-01 → 2023-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE12.5%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE12.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE10.7%2019-04-01 → 2020-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees3,853at 2024-03-31Cons.Number of employees
Employees3,761at 2023-03-31Cons.Number of employees
Employees3,687at 2022-03-31dCons.Number of employees
Employees3,607at 2021-03-31dCons.Number of employees
Employees3,560at 2020-03-31dCons.Number of employees
Revenue¥498.8bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥441.2bn2022-04-01 → 2023-03-31StandaloneNet sales
Revenue¥357.0bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥305.2bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Revenue¥286.2bn2019-04-01 → 2020-03-31dStandaloneNet sales (5-year summary)
Operating income¥187.9bn2023-04-01 → 2024-03-31StandaloneOperating income
Operating income¥152.0bn2022-04-01 → 2023-03-31StandaloneOperating income
Ordinary income¥188.0bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥150.8bn2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥121.1bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥86.8bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥70.8bn2019-04-01 → 2020-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥198.0bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Profit before tax¥148.2bn2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Net income¥152.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥117.2bn2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥94.6bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥76.9bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Net income¥69.3bn2019-04-01 → 2020-03-31dStandaloneNet income loss (5-year summary)
Total assets¥847.3bnat 2024-03-31StandaloneAssets
Total assets¥804.6bnat 2023-03-31StandaloneAssets
Total assets¥661.9bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥669.6bnat 2021-03-31dStandaloneTotal assets (5-year summary)
Total assets¥599.4bnat 2020-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥97.1bnat 2024-03-31StandaloneLiabilities
Total liabilities¥119.0bnat 2023-03-31StandaloneLiabilities
Net assets / equity¥750.2bnat 2024-03-31StandaloneNet assets
Net assets / equity¥685.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥599.2bnat 2022-03-31dStandaloneNet assets
Net assets / equity¥574.6bnat 2021-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥507.7bnat 2020-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥184.8bnat 2024-03-31StandaloneCash and deposits
Cash and deposits¥147.0bnat 2023-03-31StandaloneCash and deposits
EPS (basic)¥318.512023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥239.962022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥190.512021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥154.12020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥137.592019-04-01 → 2020-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥318.492023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥239.942022-04-01 → 2023-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥190.492021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥154.082020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥137.572019-04-01 → 2020-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥802023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥702022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥562021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥502020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥452019-04-01 → 2020-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,597.16at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,403.84at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,226.79at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,150.68at 2021-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,016.83at 2020-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio88.5%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio85.2%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio85.8%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.7%at 2020-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE21.3%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE18.2%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE16.1%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE14.2%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
ROE13.7%2019-04-01 → 2020-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued498,692,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued517,425,000at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued528,341,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued528,341,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued528,341,000at 2020-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees3,437at 2024-03-31StandaloneNumber of employees
Employees3,381at 2023-03-31StandaloneNumber of employees
Employees3,354at 2022-03-31dStandaloneNumber of employees
Employees3,319at 2021-03-31dStandaloneNumber of employees
Employees3,287at 2020-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Productsreportable segmentemployeesat 2024-03-313853 pure
Pharmaceutical Productsreportable segmentemployeesat 2024-03-313437 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,933
ItemContextValueUnit
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember-850000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-402000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_RevaluationReserveForLandMember－JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember-1252000000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember64571000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-63187000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember699274000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember54636000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_DeferredGainsOrLossesOnHedgesMember-402000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_RevaluationReserveForLandMember-3304000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember50930000000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember750205000000JPY
Doctor to doctor event and explanatory meeting related expenses sgaPrior1YearDuration_NonConsolidatedMember3356000000JPY
Doctor to doctor event and explanatory meeting related expenses sgaCurrentYearDuration_NonConsolidatedMember3694000000JPY
Promotion expenses sgaPrior1YearDuration_NonConsolidatedMember17817000000JPY
Promotion expenses sgaCurrentYearDuration_NonConsolidatedMember23981000000JPY
Salaries sgaPrior1YearDuration_NonConsolidatedMember12497000000JPY
Salaries sgaCurrentYearDuration_NonConsolidatedMember12538000000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember671000000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember-641000000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember3552000000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember3743000000JPY
Provision for directors bonuses sgaPrior1YearDuration_NonConsolidatedMember134000000JPY
Provision for directors bonuses sgaCurrentYearDuration_NonConsolidatedMember125000000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember712000000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember966000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember107865000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember112440000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-06-21
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第76期(自　2023年４月１日　至　2024年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)小野薬品工業株式会社
Company name in english cover pageFilingDateInstantONO　PHARMACEUTICAL　CO.,　LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　滝　野 　十　一
Address of registered headquarter cover pageFilingDateInstantText · Plus
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当事項はありません。
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)該当事項はありません。
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪市中央区久太郎町一丁目８番２号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪(06)6263局5670番
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経営管理統括部長　　伊　藤 　雅　樹
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00945
Fund codeFilingDateInstant－
Security codeFilingDateInstant45280
Filer name in japaneseFilingDateInstant
Original text (Japanese)小野薬品工業株式会社
Filer name in englishFilingDateInstantONO PHARMACEUTICAL CO., LTD.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2023-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass